Literature DB >> 10747109

Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy.

B Rodés1, A Holguín, V Soriano, M Dourana, K Mansinho, F Antunes, J González-Lahoz.   

Abstract

The reverse transcriptase (RT) and protease genes from 12 human immunodeficiency virus type 2 (HIV-2)-infected individuals who had been exposed to antiretroviral drugs for longer than 6 months were examined for the presence of mutations which could be involved in drug resistance. Four individuals carried virus genotypes with amino acid substitutions potentially associated with resistance to nucleoside analogues: two at codon 70 (K-->R) and two at codon 184 (M-->V). Moreover, the latter two patients harbored a codon Q151M mutation which is associated to multidrug resistance in HIV-1, and one of these subjects carried some of the typically linked mutations at codons 65 and 69. With regard to the protease inhibitors, substitutions associated with resistance to protease inhibitors at codon 46 were observed in all individuals. Moreover, minor resistance mutations, as well as new ones of unknown meaning, were often seen in the protease gene. In conclusion, amino acid changes in the HIV-2 RT and protease genes which could be associated with drug resistance seem to occur at positions identical to those for HIV-1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10747109      PMCID: PMC86447     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

Review 1.  Introduction of HIV drug-resistance testing in clinical practice.

Authors:  R Rodríguez-Rosado; C Briones; V Soriano
Journal:  AIDS       Date:  1999-06-18       Impact factor: 4.177

2.  Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases.

Authors:  A Gustchina; I T Weber
Journal:  Proteins       Date:  1991

Review 3.  Resistance to human immunodeficiency virus type 1 protease inhibitors.

Authors:  D Boden; M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

4.  Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load.

Authors:  V Soriano; P Gomes; W Heneine; A Holguín; M Doruana; R Antunes; K Mansinho; W M Switzer; C Araujo; V Shanmugam; H Lourenço; J González-Lahoz; F Antunes
Journal:  J Med Virol       Date:  2000-05       Impact factor: 2.327

5.  Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors.

Authors:  A Hizi; R Tal; M Shaharabany; M J Currens; M R Boyd; S H Hughes; J B McMahon
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

6.  Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors.

Authors:  J H Condra; E A Emini; L Gotlib; D J Graham; A J Schlabach; J A Wolfgang; R J Colonno; V V Sardana
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

7.  Identification of mixed HIV-1/HIV-2 infections in Brazil by polymerase chain reaction.

Authors:  D Pieniazek; J M Peralta; J A Ferreira; J W Krebs; S M Owen; F S Sion; C F Filho; A B Sereno; C A de Sa; B G Weniger
Journal:  AIDS       Date:  1991-11       Impact factor: 4.177

8.  The catalytic functions of chimeric reverse transcriptases of human immunodeficiency viruses type 1 and type 2.

Authors:  M Shaharabany; A Hizi
Journal:  J Biol Chem       Date:  1992-02-25       Impact factor: 5.157

9.  Resistance to nucleoside analogs of selective mutants of human immunodeficiency virus type 2 reverse transcriptase.

Authors:  M Perach; T Rubinek; A Hizi
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2.

Authors:  A G Tomasselli; J O Hui; T K Sawyer; D J Staples; C Bannow; I M Reardon; W J Howe; D L DeCamp; C S Craik; R L Heinrikson
Journal:  J Biol Chem       Date:  1990-08-25       Impact factor: 5.486

View more
  28 in total

1.  Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.

Authors:  Michel Ntemgwa; Bluma G Brenner; Maureen Oliveira; Daniela Moisi; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.

Authors:  F Damond; F Brun-Vezinet; S Matheron; G Peytavin; P Campa; S Pueyo; F Mammano; S Lastere; I Farfara; F Simon; G Chene; D Descamps
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

Review 3.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

Review 4.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

5.  Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway.

Authors:  Mar Álvarez; María Nevot; Jesús Mendieta; Miguel A Martínez; Luis Menéndez-Arias
Journal:  J Biol Chem       Date:  2017-12-22       Impact factor: 5.157

6.  In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.

Authors:  Sherie Masse; Xiaozhi Lu; Tatyana Dekhtyar; Liangjun Lu; Gennadiy Koev; Feng Gao; Hongmei Mo; Dale Kempf; Barry Bernstein; George J Hanna; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

7.  Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France.

Authors:  P Colson; M Henry; C Tourres; D Lozachmeur; H Gallais; J A Gastaut; J Moreau; C Tamalet
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

8.  Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.

Authors:  Sabelle Jallow; Abraham Alabi; Ramu Sarge-Njie; Kevin Peterson; Hilton Whittle; Tumani Corrah; Assan Jaye; Matthew Cotten; Guido Vanham; Samuel J McConkey; Sarah Rowland-Jones; Wouter Janssens
Journal:  J Clin Microbiol       Date:  2009-05-06       Impact factor: 5.948

9.  Performance characteristics of a new rapid immunochromatographic test for the detection of antibodies to human immunodeficiency virus (HIV) types 1 and 2.

Authors:  H Syed Iqbal; P Balakrishnan; K G Murugavel; Solomon Suniti
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

10.  HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in Senegal.

Authors:  Geoffrey S Gottlieb; Stephen E Hawes; Kim G Wong; Dana N Raugi; Habibatou D Agne; Cathy W Critchlow; Nancy B Kiviat; Papa Salif Sow
Journal:  AIDS Res Hum Retroviruses       Date:  2008-06       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.